妊娠期丙型肝炎治疗:是时候改变实践了
本文指出丙型肝炎病毒感染对育龄人群影响显著,围产期传播风险高达9%,且至少三分之一发生在产前。尽管产科指南因孕期直接抗病毒药物数据有限而未推荐治疗,但近年证据表明孕期使用直接抗病毒药物安全有效,治愈率与非孕期成人相似。文章建议妇产科医生通过共享决策,在孕中晚期启动治疗,并推荐使用数据较多的来迪派韦/索磷布韦和索磷布韦/维帕他韦。
要点
- 孕期直接抗病毒药物治疗安全有效,治愈率与非孕期成人相似。
- 围产期丙型肝炎病毒传播风险高达9%,至少三分之一发生在产前。
- 建议孕中晚期启动治疗,来迪派韦/索磷布韦和索磷布韦/维帕他韦数据最多。
核心结论
- 孕期使用直接抗病毒药物治疗丙型肝炎安全有效,治愈率与非孕期成人相似,应考虑改变不治疗的实践。
研究设计与样本
- 本文为综述,总结了孕期直接抗病毒药物治疗丙型肝炎的证据。
主要发现
- 围产期丙型肝炎病毒传播风险高达9%,至少三分之一发生在产前。
- 孕期直接抗病毒药物治疗的治愈率与非孕期成人相似。
- 来迪派韦/索磷布韦和索磷布韦/维帕他韦在孕期数据最多。
关键数值与推荐
- 围产期传播风险高达9%。
- 至少三分之一的传播发生在产前。
- 治疗应在孕中晚期启动。
临床怎么用
- 妇产科医生应围绕孕期丙型肝炎治疗进行共享决策。
- 治疗应在孕中晚期启动。
- 讨论中应纳入来迪派韦/索磷布韦和索磷布韦/维帕他韦。
- 母胎医学、感染科和肝病科多学科协作可促进孕期治疗可及性。
局限性
- 孕期直接抗病毒药物使用的数据仍较有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Hepatitis C virus (HCV) infection has become a public health crisis in the last few decades, with a significant impact on individuals of reproductive age. Direct-acting antivirals (DAAs) were introduced in 2011 and are highly effective at eradicating HCV infection through 8- to 12-week treatment courses, making them the mainstay of treatment for nonpregnant adults. Obstetric guidelines have not recommended treatment of HCV infection during pregnancy due to more limited data on DAA use during pregnancy. The risk of perinatal transmission of HCV is up to 9%, with at least one-third of transmissions occurring antenatally. Infant follow-up after perinatal exposure to HCV infection has been poor due to loss to care and a long latency to recommended testing. In recent years, there has been a growing body of evidence that DAAs are safe and effective in pregnancy, with similar cure rates as nonpregnant adults. Pregnancy represents a time when individuals are continuously engaged in care, providing an optimal window for treatment of HCV infection. Obstetrician/gynecologists should employ shared decision-making surrounding treatment of HCV infection during pregnancy, acknowledging the benefits and efficacy of treatment versus the available data on DAA exposure in pregnancy. Therapy should be initiated during the second or third trimesters, with limited but reassuring data on DAA exposure through breastmilk. Ledipasvir/sofosbuvir and sofosbuvir/velpatasvir currently have the most data available in pregnancy and should be included in conversations regarding HCV treatment in pregnancy. Multidisciplinary care between maternal-fetal medicine, infectious disease, and hepatology can help promote access to HCV treatment in pregnancy. El resumen está disponible en Español al final del artículo.
引用
- Dutra K, Fenkel JM. Hepatitis C treatment during pregnancy: time for a practice change. Am J Obstet Gynecol MFM. 2025. PMID: 41365430. doi:10.1016/j.ajogmf.2025.101865
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。